Biotech Company’s Needle-Free Vaccination Technology Is a Game Changer!
Biotech company Vaxxas has just closed a successful series B investment round to fund clinical trials for its needle-free vaccination technology, Nanopatch, raising AU$25 million. The technology was was developed by a research group led…






